Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Subretinal Neovascular Membranes Medication

  • Author: Steve Charles, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Sep 11, 2015
 
 

Anti-VEGF therapy

Class Summary

Reduces risk of visual loss similar to that seen with photodynamic therapy.

Pegaptanib (Macugen)

 

Selective VEGF antagonist that promotes vision stability and reduces visual acuity loss and progression to legal blindness. VEGF causes angiogenesis and increases vascular permeability and inflammation, all of which contribute to neovascularization in age-related wet macular degeneration.

 
 
Contributor Information and Disclosures
Author

Steve Charles, MD Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Macula Society, Retina Society, Club Jules Gonin

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Steve Charles, MD Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Macula Society, Retina Society, Club Jules Gonin

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

V Al Pakalnis, MD, PhD Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center

V Al Pakalnis, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, South Carolina Medical Association

Disclosure: Nothing to disclose.

References
  1. la Cour M, Kiilgaard JF, Nissen MH. Age-related macular degeneration: epidemiology and optimal treatment. Drugs Aging. 2002. 19(2):101-33. [Medline].

  2. la Cour M, Nielsen NV, Larsen M, Haamann PH, Vinding T. [Age related macular degeneration. A widespread disease]. Ugeskr Laeger. 2001 Nov 12. 163(46):6396-400. [Medline].

  3. Verma L, Das T, Binder S, et al. New approaches in the management of choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol. 2000 Dec. 48(4):263-78. [Medline].

  4. Venkatesh P, Gupta RK, Verma L, Tewari HK. Evaluation of trans-scleral diode laser using diopexy probe for subfoveal choroidal neovascular membrane in age-related macular degeneration. J Clin Laser Med Surg. 2004 Apr. 22(2):91-7. [Medline].

  5. Soubrane G, Souied E, Haddad W, et al. Alternative therapies for choroidal neovessels resulting from age-related macular degeneration [in French]. J Fr Ophtalmol. 2003 Oct. 26(8):876-8. [Medline].

  6. Soubrane G, Kuhn D, Oubraham H, Quaranta M, Coscas G. [New therapies for the treatment of age-related macular degeneration]. J Soc Biol. 2001. 195(2):115-8. [Medline].

  7. Sickenberg M. Early detection, diagnosis and management of choroidal neovascularization in age-related macular degeneration: the role of ophthalmologists. Ophthalmologica. 2001 Jul-Aug. 215(4):247-53. [Medline].

  8. Seland JH. [Age-related macular degeneration]. Tidsskr Nor Laegeforen. 2004 Jan 8. 124(1):52-4. [Medline].

  9. Rumelt S, Kaiserman I, Rehany U, Ophir A, Pikkel J, Loewenstein A. Detachment of subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2002 Dec. 134(6):822-7. [Medline].

  10. Razavi S, Coscas G, Soubrane G. [Age related macular degeneration: a review of anti-angiogenic treatments]. J Fr Ophtalmol. 2002 Sep. 25(7):747-52. [Medline].

  11. Potocky M, Trnavec B. [Etiopathogenesis of age-related macular degeneration and present possibilities of treatment]. Bratisl Lek Listy. 2000. 101(4):231-3. [Medline].

  12. Oneill C, Jamison J, McCulloch D, Smith D. Age-related macular degeneration: cost-of-illness issues. Drugs Aging. 2001. 18(4):233-41. [Medline].

  13. Mohan KC, Shukla D, Namperumalsamy P, Kim R. Management of age-related macular degeneration. J Indian Med Assoc. 2003 Aug. 101(8):471-4, 476. [Medline].

  14. Mittra RA, Singerman LJ. Recent advances in the management of age-related macular degeneration. Optom Vis Sci. 2002 Apr. 79(4):218-24. [Medline].

  15. Mittra RA. New treatments for age-related macular degeneration. Minn Med. 2003 Apr. 86(4):40-6. [Medline].

  16. La Heij EC, Liem AT, Hendrikse F. [Age-related macular degeneration; therapeutic options]. Ned Tijdschr Geneeskd. 2001 Jul 21. 145(29):1390-7. [Medline].

  17. Korner-Stiefbold U. [Age-related macular degeneration (AMD)--therapeutic possibilities and new approaches]. Ther Umsch. 2001 Jan. 58(1):28-35. [Medline].

  18. Koh AH, Ang CL. Age-related macular degeneration: what's new. Ann Acad Med Singapore. 2002 May. 31(3):399-404. [Medline].

  19. Hunt DW, Margaron P. Status of therapies in development for the treatment of age-related macular degeneration. IDrugs. 2003 May. 6(5):464-9. [Medline].

  20. Hooper CY, Guymer RH. New treatments in age-related macular degeneration. Clin Experiment Ophthalmol. 2003 Oct. 31(5):376-91. [Medline].

  21. Frennesson C, Nilsson SE. [Age-related macular degeneration--new possibilities for prophylactic measures]. Lakartidningen. 2002 Aug 8. 99(32-33):3194-7. [Medline].

  22. Fong DS. Age-related macular degeneration: update for primary care. Am Fam Physician. 2000 May 15. 61(10):3035-42. [Medline].

  23. Donati G. [Current treatment of choroidal neovascularization in age-related macular degeneration]. J Fr Ophtalmol. 2002 Sep. 25(7):740-6. [Medline].

  24. Donati G. [Treatment according to "evidence-based medicine" of aged-related exudative age-related macular degeneration (laser photocoagulation and photodynamic therapy)]. Klin Monbl Augenheilkd. 2001 May. 218(5):313-5. [Medline].

  25. Coscas F, Stanescu D, Coscas G, Soubrane G. [Feeder vessel treatment of choroidal neovascularization in age-related macular degeneration]. J Fr Ophtalmol. 2003 Jun. 26(6):602-8. [Medline].

  26. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol. 1998 Sep-Oct. 43(2):134-46. [Medline].

  27. Akduman L, Del Priore LV, Desai VN, Olk RJ, Kaplan HJ. Perfusion of the subfoveal choriocapillaris affects visual recovery after submacular surgery in presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1997 Jan. 123(1):90-6. [Medline].

  28. Parodi MB, Da Pozzo S, Ravalico G. Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia. Br J Ophthalmol. 2003 Feb. 87(2):177-83. [Medline].

  29. Wang X, Hu S. [A review of research actuality on age-related macular degeneration]. Yan Ke Xue Bao. 2001 Dec. 17(4):245-51. [Medline].

  30. Korte GE, Reppucci V, Henkind P. RPE destruction causes choriocapillary atrophy. Invest Ophthalmol Vis Sci. 1984 Oct. 25(10):1135-45. [Medline].

  31. Kuwabara T, Ishikawa Y, Kaiser-Kupfer MI. Experimental model of gyrate atrophy in animals. Ophthalmology. 1981 Apr. 88(4):331-5. [Medline].

  32. Flower RW, von Kerczek C, Zhu L, Ernest A, Eggleton C, Topoleski LD. Theoretical investigation of the role of choriocapillaris blood flow in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration. Am J Ophthalmol. 2001 Jul. 132(1):85-93. [Medline].

  33. Del Priore LV, Kaplan HJ, Hornbeck R, Jones Z, Swinn M. Retinal pigment epithelial debridement as a model for the pathogenesis and treatment of macular degeneration. Am J Ophthalmol. 1996 Nov. 122(5):629-43. [Medline].

  34. Apostol S. [Past, present, and future therapeutically options in age related macular degeneration]. Oftalmologia. 2002. 53(2):5-8. [Medline].

  35. Carstocea B, Gafencu O, Armegioiu M, et al. [Age related macular degeneration surgery]. Oftalmologia. 2002. 53(2):97-102. [Medline].

  36. Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol. 2002 Mar. 86(3):321-7. [Medline].

  37. Miskala PH, Hawkins BS, Mangione CM, et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. Arch Ophthalmol. 2003 Apr. 121(4):531-9. [Medline].

  38. Ergun E, Maar N, Radner W, Barbazetto I, Schmidt-Erfurth U, Stur M. Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2003 Jan. 110(1):65-9. [Medline].

  39. Bermig J, Tylla H, Jochmann C, Nestler A, Wolf S. Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2002 Mar. 240(3):169-75. [Medline].

  40. Torron Fernandez-Blanco C, Perez Olivan S, Melcon Sanchez-Friera B, Ferrer Novella E, Ruiz-Moreno O, Honrubia Lopez FM. [Dynamic angiography in age related macular degeneration]. Arch Soc Esp Oftalmol. 2002 Jul. 77(7):353-9. [Medline].

  41. Luke C, Aisenbrey S, Luke M, Marzella G, Bartz-Schmidt KU, Walter P. Electrophysiological changes after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol. 2001 Aug. 85(8):928-32. [Medline].

  42. Luke C, Alteheld N, Aisenbrey S, et al. Electro-oculographic findings after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2003 Sep. 241(9):710-5. [Medline].

  43. Kaiser RS, Berger JW, Williams GA, et al. Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina. 2002 Dec. 22(6):683-90. [Medline].

  44. Cekiç O, Ohji M, KesercI B, et al. Evaluation of choroidal perfusion of the new central macular area by dilution analysis of indocyanine green angiography after macular translocation. Retina. 2004 Apr. 24(2):210-4. [Medline].

  45. Stoffelns BM. [Kinetics of indocyanine green (ICG) and clinical use for enhancement of transpupillary thermotherapy (TTT) in hypopigmented small choroidal melanomas]. Klin Monbl Augenheilkd. 2004 May. 221(5):374-8. [Medline].

  46. Kent DL, Fujii GY, Pieramici DJ, et al. Angiographic characteristics in patients undergoing macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina. 2003 Apr. 23(2):152-8. [Medline].

  47. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology. 2003 Feb. 110(2):400-5. [Medline].

  48. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol. 2002 Jun. 86(6):663-9. [Medline].

  49. Farah ME, Cardillo JA, Luzardo AC, Calucci D, Williams GA, Costa RA. Indocyanine green mediated photothrombosis for the management of predominantly classic choroidal neovascularisation caused by age related macular degeneration. Br J Ophthalmol. 2004 Aug. 88(8):1055-9. [Medline].

  50. Montero JA, Ruiz-Moreno JM, Tavolato M. Follow-up of age-related macular degeneration patients treated by photodynamic therapy with optical coherence tomography 3. Graefes Arch Clin Exp Ophthalmol. 2003 Oct. 241(10):797-802. [Medline].

  51. Witkin AJ, Vuong LN, Srinivasan VJ, et al. High-speed ultrahigh resolution optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmology. 2009 May. 116(5):956-63. [Medline]. [Full Text].

  52. Bereczki A, Toth J, Suveges I. Histological examination of the pigment epithelium-Bruch membrane-chorio-capillaris complex after macular translocation. Br J Ophthalmol. 2000 May. 84(5):550-1. [Medline].

  53. Castellarin AA, Sugino IK, Nasir M, Zarbin MA. Clinicopathological correlation of an excised choroidal neovascular membrane in pseudotumour cerebri. Br J Ophthalmol. 1997 Nov. 81(11):994-1000. [Medline].

  54. Mozaffarieh M, Sacu S, Wedrich A. The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: a review based on controversial evidence. Nutr J. 2003 Dec 11. 2:20. [Medline]. [Full Text].

  55. Vadala M, Pece A, Cipolla S, et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol. 2011 May. 95(5):657-61. [Medline].

  56. Mones JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond). 2009 Jun. 23(6):1275-80; quiz 1281. [Medline].

  57. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2009 May 20. [Medline].

  58. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5. 355(14):1419-31. [Medline].

  59. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5. 355(14):1432-44. [Medline].

  60. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009 Jan. 116(1):57-65.e5. [Medline].

  61. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009 Jun. 116(6):1225.e1. [Medline].

  62. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1991 Jan 15. 111(1):1-7. [Medline].

  63. Schmidt JC, Rodrigues EB, Meyer CH, Kroll P. Is membrane extraction in cases of exudative age-related macular degeneration still up-to-date? A 4-year résumé. Ophthalmologica. 2003 Nov-Dec. 217(6):401-7. [Medline].

  64. Pollack JS, Del Priore LV, Smith ME, Feiner MA, Kaplan HJ. Postoperative abnormalities of the choriocapillaris in exudative age-related macular degeneration. Br J Ophthalmol. 1996 Apr. 80(4):314-8. [Medline]. [Full Text].

  65. Castellarin AA, Nasir M, Sugino IK, Zarbin MA. Progressive presumed choriocapillaris atrophy after surgery for age-related macular degeneration. Retina. 1998. 18(2):143-9. [Medline].

  66. Zhang X, Bok D. Transplantation of retinal pigment epithelial cells and immune response in the subretinal space. Invest Ophthalmol Vis Sci. 1998 May. 39(6):1021-7. [Medline].

  67. Algvere PV, Berglin L, Gouras P, Sheng Y. Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1994 Dec. 232(12):707-16. [Medline].

  68. Algvere PV, Berglin L, Gouras P, Sheng Y, Kopp ED. Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy. Graefes Arch Clin Exp Ophthalmol. 1997 Mar. 235(3):149-58. [Medline].

  69. Aramant RB, Seiler MJ, Ball SL. Successful cotransplantation of intact sheets of fetal retina with retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1999 Jun. 40(7):1557-64. [Medline].

  70. Del Priore LV, Hornbeck R, Kaplan HJ, et al. Débridement of the pig retinal pigment epithelium in vivo. Arch Ophthalmol. 1995 Jul. 113(7):939-44. [Medline].

  71. Joussen AM. How complete is successful? "Autologous retinal pigment epithelium and choriod translocation in patients with exsudative age-related macular degeneration: a short-term follow-up" by Jan van Meurs and P.R. van Biesen. Graefes Arch Clin Exp Ophthalmol. 2003 Dec. 241(12):966-7. [Medline].

  72. Lane C, Boulton M, Marshall J. Transplantation of retinal pigment epithelium using a pars plana approach. Eye (Lond). 1989. 3 ( Pt 1):27-32. [Medline].

  73. Lappas A, Weinberger AW, Foerster AM, Kube T, Rezai KA, Kirchhof B. Iris pigment epithelial cell translocation in exudative age-related macular degeneration. A pilot study in patients. Graefes Arch Clin Exp Ophthalmol. 2000 Aug. 238(8):631-41. [Medline].

  74. Lavail MM, Li L, Turner JE, Yasumura D. Retinal pigment epithelial cell transplantation in RCS rats: normal metabolism in rescued photoreceptors. Exp Eye Res. 1992 Oct. 55(4):555-62. [Medline].

  75. Mueller-Jensen K, Machemer R, Azarnia R. Autotransplantation of retinal pigment epithelium in intravitreal diffusion chamber. Am J Ophthalmol. 1975 Sep. 80(3 Pt 2):530-7. [Medline].

  76. Peyman GA, Blinder KJ, Paris CL, Alturki W, Nelson NC Jr, Desai U. A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring. Ophthalmic Surg. 1991 Feb. 22(2):102-8. [Medline].

  77. Seaton AD, Turner JE. RPE transplants stabilize retinal vasculature and prevent neovascularization in the RCS rat. Invest Ophthalmol Vis Sci. 1992 Jan. 33(1):83-91. [Medline].

  78. Semkova I, Kreppel F, Welsandt G, et al. Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci U S A. 2002 Oct 1. 99(20):13090-5. [Medline].

  79. Stanga PE, Kychenthal A, Fitzke FW, et al. Retinal pigment epithelium translocation and central visual function in age related macular degeneration: preliminary results. Int Ophthalmol. 2001. 23(4-6):297-307. [Medline].

  80. Stanga PE, Kychenthal A, Fitzke FW, et al. Retinal pigment epithelium translocation after choroidal neovascular membrane removal in age-related macular degeneration. Ophthalmology. 2002 Aug. 109(8):1492-8. [Medline].

  81. van Meurs JC, Van Den Biesen PR. Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: short-term follow-up. Am J Ophthalmol. 2003 Oct. 136(4):688-95. [Medline].

  82. Binder S, Krebs I, Hilgers RD, et al. Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial. Invest Ophthalmol Vis Sci. 2004 Nov. 45(11):4151-60. [Medline].

  83. Valentino TL, Kaplan HJ, Del Priore LV, Fang SR, Berger A, Silverman MS. Retinal pigment epithelial repopulation in monkeys after submacular surgery. Arch Ophthalmol. 1995 Jul. 113(7):932-8. [Medline].

  84. Yamaguchi K, Yamaguchi K, Young RW, et al. Vitreoretinal surgical technique for transplanting retinal pigment epithelium in rabbit retina. Jpn J Ophthalmol. 1992. 36(2):142-50. [Medline].

  85. Mueller-Jensen K, Mandelcorn MS. Membrane formation by autotransplanted retinal pigment epithelium. Mod Probl Ophthalmol. 1975. 15:228-34.

  86. Lappas A, Foerster AM, Weinberger AW, Coburger S, Schrage NF, Kirchhof B. Translocation of iris pigment epithelium in patients with exudative age-related macular degeneration: long-term results. Graefes Arch Clin Exp Ophthalmol. 2004 Aug. 242(8):638-47. [Medline].

  87. Abdel-Meguid A, Lappas A, Hartmann K, et al. One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol. 2003 May. 87(5):615-21. [Medline].

  88. Aisenbrey S, Bartz-Schmidt U. Macular translocation with 360-degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol. 2003 May. 135(5):748-9; author reply 749. [Medline].

  89. Aisenbrey S, Lafaut B, Szurman P, et al. [Macular translocation with 360 degree retinotomy in the treatment if exudative macular degeneration. Functional and angiographic results]. Ophthalmologe. 2002 Mar. 99(3):164-70. [Medline].

  90. Aisenbrey S, Lafaut BA, Szurman P, et al. Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol. 2002 Apr. 120(4):451-9. [Medline].

  91. Akduman L, Karavellas MP, MacDonald JC, Olk RJ, Freeman WR. Macular translocation with retinotomy and retinal rotation for exudative age-related macular degeneration. Retina. 1999. 19(5):418-23. [Medline].

  92. Albini TA, Rao NA, Li A, Craft CM, Fujii GY, De Juan E Jr. Limited macular translocation: a clinicopathologic case report. Ophthalmology. 2004 Jun. 111(6):1209-14. [Medline].

  93. American Academy of Ophthalmology. Macular translocation. American Academy of Ophthalmology. Ophthalmology. 2000 May. 107(5):1015-8. [Medline].

  94. Au Eong KG, Pieramici DJ, Fujii GY, et al. Macular translocation: unifying concepts, terminology, and classification. Am J Ophthalmol. 2001 Feb. 131(2):244-53. [Medline].

  95. Benner JD, Meyer CH, Shirkey BL, Toth CA. Macular translocation with radial scleral ouffolding: experimental studies and initial human results. Graefes Arch Clin Exp Ophthalmol. 2001 Nov. 239(11):815-23. [Medline].

  96. Benner JD, Sunness JS, Ziegler MD, Soltanian J. Limited macular translocation for atrophic maculopathy. Arch Ophthalmol. 2002 May. 120(5):586-91. [Medline].

  97. Cahill MT, Freedman SF, Toth CA. Macular translocation with 360 degrees peripheral retinectomy for geographic atrophy. Arch Ophthalmol. 2003 Jan. 121(1):132-3. [Medline].

  98. Cekiç O, Keserci B, Ohji M, et al. Macular translocation surgery and retinal circulation times. Retina. 2004 Feb. 24(1):51-6. [Medline].

  99. Cekic O, Ohji M, Tano Y, Chang S. Continuous outflow devices for macular translocation with 360-degree retinotomy. Am J Ophthalmol. 2003 Feb. 135(2):241-3. [Medline].

  100. Chang AA, Tan W, Beaumont PE, Zeldovich A. Limited macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration. Clin Experiment Ophthalmol. 2003 Apr. 31(2):103-9. [Medline].

  101. D'Amico DJ, Friberg TR. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2001 Aug. 132(2):289-90. [Medline].

  102. Deramo VA, Meyer CH, Toth CA. Successful macular translocation with temporary scleral infolding using absorbable sture. Retina. 2001. 21(4):304-11. [Medline].

  103. Dolezalova J, Rusnak S. [Macular translocation--first experience]. Cesk Slov Oftalmol. 2004 Jul. 60(4):239-47. [Medline].

  104. Eckardt C, Eckardt U. Macular translocation in nonexudative age-related macular degeneration. Retina. 2002 Dec. 22(6):786-94. [Medline].

  105. Eckardt C, Eckardt U, Groos S, Luciano L, Reale E. Macular translocation in a patient with adult-onset foveomacular vitelliform dystrophy with light- and electron-microscopic observations on the surgically removed subfoveal tissue. Graefes Arch Clin Exp Ophthalmol. 2004 Jun. 242(6):456-67. [Medline].

  106. Fang X, Hayashi A, Morimoto T, et al. Retinal changes after macular translocation with 360-degree retinotomy in monkey eyes. Am J Ophthalmol. 2004 Jun. 137(6):1034-41. [Medline].

  107. Faude F, Wendt S, Biedermann B, et al. Facilitation of artificial retinal detachment for macular translocation surgery tested in rabbit. Invest Ophthalmol Vis Sci. 2001 May. 42(6):1328-37. [Medline].

  108. Faude F, Wiedemann P, Reichenbach A. A "detachment infusion" for macular translocation surgery. Retina. 1999. 19(2):173-4. [Medline].

  109. Fujii GY, Au Eong KG, Humayun MS, de Juan E Jr. Limited macular translocation: current concepts. Ophthalmol Clin North Am. 2002 Dec. 15(4):425-36. [Medline].

  110. Fujii GY, de Juan E Jr, Au Eong KG, Harlan JB Jr. Effective nasal limited macular translocation. Am J Ophthalmol. 2001 Jul. 132(1):124-6. [Medline].

  111. Fujii GY, de Juan E Jr, Humayun MS, Chang TS. Limited macular translocation for the management of subfoveal choroidal neovascularization after photodynamic therapy. Am J Ophthalmol. 2003 Jan. 135(1):109-12. [Medline].

  112. Fujii GY, de Juan E Jr, Pieramici DJ, et al. Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am J Ophthalmol. 2002 Jul. 134(1):69-74. [Medline].

  113. Fujii GY, de Juan E Jr, Sunness J, Humayun MS, Pieramici DJ, Chang TS. Patient selection for macular translocation surgery using the scanning laser ophthalmoscope. Ophthalmology. 2002 Sep. 109(9):1737-44. [Medline].

  114. Fujii GY, de Juan E, Thomas MA, Pieramici DJ, Humayun MS, Au Eong KG. Limited macular translocation for the management of subfoveal retinal pigment epithelial loss after submacular surgery. Am J Ophthalmol. 2001 Feb. 131(2):272-5. [Medline].

  115. Fujii GY, Humayun MS, Pieramici DJ, Schachat AP, Au Eong KG, de Juan E Jr. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol. 2001 Jan. 131(1):90-100. [Medline].

  116. Glacet-Bernard A, Kuhn D, Coscas F, Coscas G, Soubrane G. [Translocation of the macula for retrofoveal choroidal neovascularization in age-related macular degeneration and severe myopia: first results]. J Fr Ophtalmol. 2000 Jun. 23(6):576-81. [Medline].

  117. Glacet-Bernard A, Simon P, Hamelin N, Coscas G, Soubrane G. Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia. Am J Ophthalmol. 2001 Jan. 131(1):78-89. [Medline].

  118. Gleadall R, Navarro VB, Dejuan E. Macular translocation--what our patients need to know. Insight. 2001 Jul-Sep. 26(3):73-6. [Medline].

  119. Grossniklaus HE, Brooks HL Jr, Sippy BD, Liu P. Retinal translocation and photodynamic therapy for age-related macular degeneration with classic choroidal neovascularization: a clinicopathologic case report. Retina. 2002 Dec. 22(6):818-24. [Medline].

  120. Gutierrez Amoros J, Gutierrez Amoros C. [Macular translocation in myopic patient wearing a phakic intraocular lens]. Arch Soc Esp Oftalmol. 2002 Feb. 77(2):99-101. [Medline].

  121. Güven D, Panzan CQ, Humayun MS, De Juan E Jr. Use of rotational sutures for limited retinal translocation: a new technique for superior limited macular translocation. Am J Ophthalmol. 2004 May. 137(5):901-7. [Medline].

  122. Haller JA, Hartranft CD, Fujii GY, Pieramici D, Humayun MS, de Juan E Jr. Limited macular translocation for neovascular maculopathy. Semin Ophthalmol. 2000 Jun. 15(2):81-7. [Medline].

  123. Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol. 2002 Apr. 133(4):530-6. [Medline].

  124. Ho CL. Macular translocation--an innovative treatment for macular degenerative diseases. Chang Gung Med J. 2000 Nov. 23(11):672-80. [Medline].

  125. Ichibe M, Imai K, Ohta M, Oya Y, Yoshizawa T, Abe H. Simultaneous translocation of the macula and underlying retinal pigment epithelium during macular translocation surgery in a patient with long standing myopic neovascular maculopathy. Br J Ophthalmol. 2003 Mar. 87(3):371-2. [Medline].

  126. Kamei M, Roth DB, Lewis H. Macular translocation with chorioscleral outfolding: an experimental study. Am J Ophthalmol. 2001 Aug. 132(2):149-55. [Medline].

  127. Kamei M, Tano Y, Yasuhara T, et al. Macular translocation with chorioscleral outfolding: 2-year results. Am J Ophthalmol. 2004 Oct. 138(4):574-81. [Medline].

  128. Koh SS, Arroyo J. Macular translocation with 360-degree retinotomy for treatment of exudative age-related macular degeneration. Int Ophthalmol Clin. 2004 Winter. 44(1):73-81. [Medline].

  129. Kubota A, Harino S, Ohji M, Tano Y. Modified technique to create retinal detachment during macular translocation surgery. Am J Ophthalmol. 2003 Jan. 135(1):105-6. [Medline].

  130. Landau K, Messmer E. [Translocation of the retina in senile macular degeneration]. Schweiz Med Wochenschr. 1999 Jan 12. 129(1-2):49-51. [Medline].

  131. Lewis H. Macular translocation with chorioscleral outfolding: a pilot clinical study. Am J Ophthalmol. 2001 Aug. 132(2):156-63. [Medline].

  132. Lewis H, Kaiser PK, Lewis S, Estafanous M. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: a prospective study. Am J Ophthalmol. 1999 Aug. 128(2):135-46. [Medline].

  133. Lin SB, Glaser BM, Gould D, Baudo TA, Lakhanpal RR, Murphy RP. Scleral outfolding for macular translocation. Am J Ophthalmol. 2000 Jul. 130(1):76-81. [Medline].

  134. Machemer R. Macular translocation. Am J Ophthalmol. 1998 May. 125(5):698-700. [Medline].

  135. McLeod D. Foveal translocation for exudative age related macular degeneration. Br J Ophthalmol. 2000 Apr. 84(4):344-5. [Medline].

  136. Morizane Y, Shiraga F, Takasu I, Yumiyama S, Okanouchi T, Ohtsuki H. Selection for inferior limited macular translocation on the basis of distance from the fovea to the inferior edge of the subfoveal choroidal neovascularization. Am J Ophthalmol. 2002 Jun. 133(6):848-50. [Medline].

  137. Ng EW, Fujii GY, Au Eong KG, et al. Macular translocation in patients with recurrent subfoveal choroidal neovascularization after laser photocoagulation for nonsubfoveal choroidal neovascularization. Ophthalmology. 2004 Oct. 111(10):1889-93. [Medline].

  138. Ohji M, Fujikado T, Kusaka S, et al. Comparison of three techniques of foveal translocation in patients with subfoveal choroidal neovascularization resulting from age-related macular degeneration. Am J Ophthalmol. 2001 Dec. 132(6):888-96. [Medline].

  139. Park CH, Toth CA. Macular translocation surgery with 360-degree peripheral retinectomy following ocular photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2003 Nov. 136(5):830-5. [Medline].

  140. Pawlak D, Glacet-Bernard A, Papp M, Roquet W, Coscas G, Soubrane G. Limited macular translocation compared with photodynamic therapy in the management of subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2004 May. 137(5):880-7. [Medline].

  141. Pertile G, Claes C. Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol. 2002 Oct. 134(4):560-5. [Medline].

  142. Pieramici DJ, De Juan E Jr, Fujii GY, et al. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2000 Oct. 130(4):419-28. [Medline].

  143. Pieramici DJ, de Juna E Jr. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2001 Jul. 132(1):139-40. [Medline].

  144. Potter MJ, Chang TS, Lee AS, Rai S. Improvement in macular function after retinal translocation surgery in a patient with age-related macular degeneration. Am J Ophthalmol. 2000 Apr. 129(4):547-9. [Medline].

  145. Roig-Melo EA, Afaro DV 3rd, Heredia-Elizondo ML, et al. Macular translocation: histopathologic findings in swine eyes. Eur J Ophthalmol. 2000 Oct-Dec. 10(4):297-303. [Medline].

  146. Roth DB, Estafanous M, Lewis H. Macular translocation for subfoveal choroidal neovascularization in angioid streaks. Am J Ophthalmol. 2001 Mar. 131(3):390-2. [Medline].

  147. Sato M, Terasaki H, Ogino N, et al. Strabological findings after macular translocation surgery with 360 degrees retinotomy. Invest Ophthalmol Vis Sci. 2003 May. 44(5):1939-44. [Medline].

  148. Simon P, Glacet-Bernard A, Coscas G, Soubrane G. [Progression of choroidal neovascularization after macular translocation in age-related macular degeneration and degenerative myopia]. J Fr Ophtalmol. 2002 Sep. 25(7):694-700. [Medline].

  149. Sullivan P, Filsecker L, Sears J. Limited macular translocation with scleral retraction suture. Br J Ophthalmol. 2002 Apr. 86(4):434-9. [Medline].

  150. Terasaki H. Rescue of retinal function by macular translocation surgery in age-related macular degeneration and other diseases with subfoveal choroidal neovascularization. Nagoya J Med Sci. 2001 May. 64(1-2):1-9. [Medline].

  151. Terasaki H, Ishikawa K, Suzuki T, Nakamura M, Miyake K, Miyake Y. Morphologic and angiographic assessment of the macula after macular translocation surgery with 360 degrees retinotomy. Ophthalmology. 2003 Dec. 110(12):2403-8. [Medline].

  152. Terasaki H, Miyake Y, Suzuki T, et al. Change in full-field ERGs after macular translocation surgery with 360 degrees retinotomy. Invest Ophthalmol Vis Sci. 2002 Feb. 43(2):452-7. [Medline].

  153. Toth CA, Freedman SF. Macular translocation with 360-degree peripheral retinectomy impact of technique and surgical experience on visual outcomes. Retina. 2001. 21(4):293-303. [Medline].

  154. Wirostko WJ, Mittra RA, Rao PK, Borrillo JL, Dev S, Mieler WF. A combination light-pipe, soft-tipped suction, and infusion cannula instrument for macular translocation. Am J Ophthalmol. 2000 Apr. 129(4):549-51. [Medline].

  155. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology. 2004 Sep. 111(9):1715-24. [Medline].

  156. Lai JC, Lapolice DJ, Stinnett SS, et al. Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch Ophthalmol. 2002 Oct. 120(10):1317-24. [Medline].

  157. Kirchhof B. [Macular translocation. Improved prognosis for age-related macular degeneration]. Ophthalmologe. 2002 Mar. 99(3):143. [Medline].

  158. Ichibe M, Yoshizawa T, Funaki S, et al. Severe hypotony after macular translocation surgery with 360-degree retinotomy. Am J Ophthalmol. 2002 Jul. 134(1):139-41. [Medline].

  159. Fujikado T, Asonuma S, Ohji M, et al. Reading ability after macular translocation surgery with 360-degree retinotomy. Am J Ophthalmol. 2002 Dec. 134(6):849-56. [Medline].

  160. Fujii GY, De Juan E Jr, Zarbin MA, Humayun MS, Au Eong KG, Phillips S. Unintentional transplantation of autologous retinal pigment epithelium during limited macular translocation. Retina. 2001. 21(4):380-2. [Medline].

  161. Cekic O, Ohji M, Hayashi A, Fujikado T, Tano Y. Foveal translocation surgery in age-related macular degeneration. Lancet. 1999 Jul 24. 354(9175):340. [Medline].

  162. Jonas JB, Panda-Jonas S. Retinorhexis in macular translocation. Br J Ophthalmol. 2000 Oct. 84(10):1208. [Medline].

  163. Neugebauer A, Fricke J. [Sensory problems after macular translocation]. Ophthalmologe. 2002 Mar. 99(3):156-9. [Medline].

  164. Oyagi T, Fujikado T, Hosohata J, et al. Foveal sensitivity and fixation stability before and after macular translocation with 360-degree retinotomy. Retina. 2004 Aug. 24(4):548-55. [Medline].

  165. Sterker I, Wolf S, Wiedemann P. Strabological results in patients with macular translocation surgery and counterrotation of the globe as a secondary procedure. Strabismus. 2002 Jun. 10(2):111-7. [Medline].

  166. Terasaki H, Ishikawa K, Niwa Y, et al. Changes in focal macular ERGs after macular translocation surgery with 360 degrees retinotomy. Invest Ophthalmol Vis Sci. 2004 Feb. 45(2):567-73. [Medline].

  167. Toth CA, Lapolice DJ, Banks AD, Stinnett SS. Improvement in near visual function after macular translocation surgery with 360-degree peripheral retinectomy. Graefes Arch Clin Exp Ophthalmol. 2004 Jul. 242(7):541-8. [Medline].

  168. Vander JF. Macular translocation. Curr Opin Ophthalmol. 2000 Jun. 11(3):159-65. [Medline].

  169. Wolf S, Lappas A, Weinberger AW, Kirchhof B. Macular translocation for surgical management of subfoveal choroidal neovascularizations in patients with AMD: first results. Graefes Arch Clin Exp Ophthalmol. 1999 Jan. 237(1):51-7. [Medline].

  170. Zrenner E. Macular translocation in adult-onset vitelliform macular dystrophy: a therapy to be recommended?. Graefes Arch Clin Exp Ophthalmol. 2004 Jun. 242(6):453-5. [Medline].

  171. de Juan E Jr, Fujii GY. Limited macular translocation. Eye (Lond). 2001 Jun. 15:413-23. [Medline].

  172. de Juan E Jr, Vander JF. Effective macular translocation without scleral imbrication. Am J Ophthalmol. 1999 Sep. 128(3):380-2. [Medline].

  173. Au Eong KG, Fujii GY, Ng EW, Humayun MS, Pieramici DJ, de Juan E Jr. Transient formed visual hallucinations following macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2001 May. 131(5):664-6. [Medline].

  174. Fujii GY, Pieramici DJ, Humayun MS, et al. Complications associated with limited macular translocation. Am J Ophthalmol. 2000 Dec. 130(6):751-62. [Medline].

  175. Kadonosono K, Takeuchi S, Iwata S, Uchio E, Itoh N, Akura J. Macular fold after limited macular translocation treated with scleral shortening release and intravitreal gas. Am J Ophthalmol. 2001 Nov. 132(5):790-2. [Medline].

  176. Kim T, Krishnasamy S, Meyer CH, Toth CA. Induced corneal astigmatism after macular translocation surgery with scleral infolding. Ophthalmology. 2001 Jul. 108(7):1203-8. [Medline].

  177. Buffenn AN, de Juan E, Fujii G, Hunter DG. Diplopia after limited macular translocation surgery. J AAPOS. 2001 Dec. 5(6):388-94. [Medline].

  178. Akyurt A. [Cyclotropia and surgical treatment after macular translocation]. Klin Monbl Augenheilkd. 2002 Jan-Feb. 219(1-2):50-4. [Medline].

  179. Freedman SF, Gearinger MD, Enyedi LB, Holgado S, Toth CA. Measurement of ocular torsion after macular translocation: disc fovea angle and Maddox rod. J AAPOS. 2003 Apr. 7(2):103-7. [Medline].

  180. Freedman SF, Holgado S, Enyedi LB, Toth CA. Management of ocular torsion and diplopia after macular translocation for age-related macular degeneration: prospective clinical study. Am J Ophthalmol. 2003 Oct. 136(4):640-8. [Medline].

  181. Freedman SF, Rojas M, Toth CA. Strabismus surgery for large-angle cyclotorsion after macular translocation surgery. J AAPOS. 2002 Jun. 6(3):154-62. [Medline].

  182. Freedman SF, Seaber JH, Buckley EG, Enyedi LB, Toth CA. Combined superior oblique muscle recession and inferior oblique muscle advancement and transposition for cyclotorsion associated with macular translocation surgery. J AAPOS. 2000 Apr. 4(2):75-83. [Medline].

  183. Fricke J, Neugebauer A. [Surgical eye muscle counter-rotation after macular translocation]. Ophthalmologe. 2002 Mar. 99(3):160-3. [Medline].

  184. Fricke J, Neugebauer A, Nobis H, Bartz-Schmidt KU, Russmann W. Counterrotation of the globe in macular translocation. Graefes Arch Clin Exp Ophthalmol. 2000 Aug. 238(8):664-8. [Medline].

  185. Ohtsuki H, Shiraga F, Hasebe S, Kono R, Yamane T, Fujiwara H. Correction of cyclovertical strabismus induced by limited macular translocation in a case of age-related macular degeneration. Am J Ophthalmol. 2001 Feb. 131(2):270-2. [Medline].

  186. Ohtsuki H, Shiraga F, Morizane Y, Furuse T, Takasu I, Hasebe S. Transposition of the anterior superior oblique insertion as a treatment for excyclotorsion induced from limited macular translocation. Am J Ophthalmol. 2004 Jan. 137(1):125-34. [Medline].

  187. Seaber JH, Machemer R. Adaptation to monocular torsion after macular translocation. Graefes Arch Clin Exp Ophthalmol. 1997 Feb. 235(2):76-81. [Medline].

  188. Stappler T, Stanga P, Groenewald C, El Bably I, Wong D. Measurement of cyclotorsion in a patient following macular translocation surgery using a modified version of the Watzke-Allen test. Retina. 2003 Apr. 23(2):250-2. [Medline].

  189. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002 Mar-Apr. 15(2):142-52. [Medline].

  190. American Academy of Ophthalmology. Photodynamic therapy with verteporfin for age-related macular degeneration. American Academy of Ophthalmology. Ophthalmology. 2000 Dec. 107(12):2314-7. [Medline].

  191. Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol. 2004 Oct. 88(10):1270-3. [Medline].

  192. Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol. 2004 Apr. 137(4):683-96. [Medline].

  193. Augustin AJ. [Photodynamic therapy with Vsudyne (Verteporfin)--an innovative therapy of age-related macular degeneration]. Krankenpfl J. 2000 Oct. 38(9-10):342-3. [Medline].

  194. Axer-Siegel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol. 2004 Apr. 122(4):453-9. [Medline].

  195. Axer-Siegel R, Ehrlich R, Yassur Y, et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns. Am J Ophthalmol. 2004 Feb. 137(2):258-64. [Medline].

  196. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina. 2004 Feb. 24(1):1-12. [Medline].

  197. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol. 2003 Sep. 121(9):1253-68. [Medline].

  198. Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'. Eye (Lond). 2004 Aug. 18(8):809-13. [Medline].

  199. Battaglia Parodi M, Da Pozzo S. Hot spots after photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina. 2002 Oct. 22(5):671-3. [Medline].

  200. Beck RW. Photodynamic therapy for age-related macular degeneration. Am J Ophthalmol. 2004 Sep. 138(3):513; author reply 513-4. [Medline].

  201. Bessler NM. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. Retina. 2004 Aug. 24(4):512-20. [Medline].

  202. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003 Apr. 110(4):667-73. [Medline].

  203. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol. 2002 Oct. 120(10):1307-14. [Medline].

  204. Bressler NM. Age related macular degeneration. New hope for a common problem comes from photodynamic therapy. BMJ. 2000 Dec 9. 321(7274):1425-7. [Medline].

  205. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001 Feb. 119(2):198-207. [Medline].

  206. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002 Nov. 120(11):1443-54. [Medline].

  207. Chan WM, Lam DS, Liu DT, Wong TH, Yuen KS. Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery. Br J Ophthalmol. 2003 Sep. 87(9):1188-9. [Medline].

  208. Costa RA, Farah ME, Cardillo JA, Belfort R Jr. Photodynamic therapy with indocyanine green for occult subfoveal choroidal neovascularization caused by age-related macular degeneration. Curr Eye Res. 2001 Oct. 23(4):271-5. [Medline].

  209. Desmettre T, Cohen SY, Mordon S. [Photodynamic therapy and age-related macular degeneration in 2000]. J Fr Ophtalmol. 2001 Jan. 24(1):82-93. [Medline].

  210. Donati G, Kapetanios AD, Pournaras CJ. Principles of treatment of choroidal neovascularization with photodynamic therapy in age-related macular degeneration. Semin Ophthalmol. 1999 Mar. 14(1):2-10. [Medline].

  211. Eter N, Vogel A, Inhetvin-Hutter C, Spitznas M. Interval reduction of photodynamic therapy (PDT) in age-related macular degeneration (AMD) is not advantageous. A pilot project [in German]. Ophthalmologe. 2003 Apr. 100(4):314-7. [Medline].

  212. Fine SL. Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration. Arch Ophthalmol. 1999 Oct. 117(10):1400-2. [Medline].

  213. Foot B, Foy R, Chakravarthy U, Wormald R. Introduction of photodynamic therapy for the treatment of neovascular age-related macular degeneration: tracking a moving target. Eye (Lond). 2003 Jul. 17(5):583-6. [Medline].

  214. Franks W. Photodynamic therapy for age-related macular degeneration. Age Ageing. 2002 Jan. 31(1):5-6. [Medline].

  215. Gaynes BI, Fiscella RG. Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration. Expert Opin Drug Saf. 2004 Jul. 3(4):345-61. [Medline].

  216. Hamon F, Goeminne P. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD. Semin Ophthalmol. 2001 Dec. 16(4):223-32. [Medline].

  217. Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol. 2004 Apr. 88(4):450-4. [Medline].

  218. Jaakkola A. [Photodynamic therapy of age-related macular degeneration]. Duodecim. 2002. 118(8):813-9. [Medline].

  219. Jin C, Ge J, Zhou S, et al. Photodynamic therapy for age-related macular degeneration. Yan Ke Xue Bao. 2004 Sep. 20(3):158-62. [Medline].

  220. Karacorlu M, Karacorlu S, Ozdemir H. Photodynamic therapy with delayed light application for the treatment of bilateral subfoveal choroidal neovascularization in age-related macular degeneration. Jpn J Ophthalmol. 2003 Nov-Dec. 47(6):595-8. [Medline].

  221. Kubicka-Trzaska A, Starzycka M. [Photodynamic therapy with indocyanine green for choroidal neovascularization caused by age-related macular degeneration--a preliminary record]. Klin Oczna. 2003. 105(6):351-4. [Medline].

  222. Messmer KJ, Abel SR. Verteporfin for age-related macular degeneration. Ann Pharmacother. 2001 Dec. 35(12):1593-8. [Medline].

  223. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999 Sep. 117(9):1161-73. [Medline].

  224. Piermarocchi S, Lo Giudice G, Sartore M, et al. Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration. Am J Ophthalmol. 2002 Apr. 133(4):572-5. [Medline].

  225. Rechtman E, Ciulla TA, Criswell MH, Pollack A, Harris A. An update on photodynamic therapy in age-related macular degeneration. Expert Opin Pharmacother. 2002 Jul. 3(7):931-8. [Medline].

  226. Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4. Retina. 2002 Oct. 22(5):536-44. [Medline].

  227. Sawa M, Chan WM, Ohji M, et al. Successful photodynamic therapy with verteporfin for recurrent choroidal neovascularization beneath the new fovea after macular translocation surgery with 360-degree retinotomy. Am J Ophthalmol. 2003 Sep. 136(3):560-3. [Medline].

  228. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000 Nov-Dec. 45(3):195-214. [Medline].

  229. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999 Sep. 117(9):1177-87. [Medline].

  230. Scorolli L, Scalinci SZ, Limoli PG, et al. [Photodynamic therapy for age related macular degeneration with and without antioxidants]. Can J Ophthalmol. 2002 Dec. 37(7):399-404. [Medline].

  231. Sharma S. Update in retina: photodynamic therapy for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Can J Ophthalmol. 2001 Feb. 36(1):7-10. [Medline].

  232. Sharma S, Bakal J, Oliver-Fernandez A, Blair J. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: results of an effectiveness study. Arch Ophthalmol. 2004 Jun. 122(6):853-6. [Medline].

  233. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2001 Nov. 108(11):2051-9. [Medline].

  234. Sivaprasad S, Hammond CJ, Jackson H. Photodynamic therapy for age-related macular degeneration. Eye (Lond). 2005 Sep. 19(9):1027-8. [Medline].

  235. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol. 2004 Sep. 88(9):1107-12. [Medline].

  236. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003 Sep. 136(3):407-18. [Medline].

  237. van den Bergh H, Ballini JP, Sickenberg M. On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration. J Fr Ophtalmol. 2004 Jan. 27(1):75-8. [Medline].

  238. van den Bergh H. Photodynamic therapy of age-related macular degeneration: History and principles. Semin Ophthalmol. 2001 Dec. 16(4):181-200. [Medline].

  239. Yassur Y, Weinberger D, Goldstein M, Loewenstein A. [Photodynamic therapy in age-related macular degeneration]. Harefuah. 2000 Sep. 139(5-6):220-3. [Medline].

  240. Wykrota H, Gierek-Lapinska A. [Photodynamic therapy in age-related macular degeneration--results of one year observation]. Klin Oczna. 2002. 104(3-4):239-43. [Medline].

  241. Wu L, Murphy RP. Photodynamic therapy: a new approach to the treatment of choroidal neovascularization secondary to age-related macular degeneration. Curr Opin Ophthalmol. 1999 Jun. 10(3):217-20. [Medline].

  242. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2003. CD002030. [Medline].

  243. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2001. CD002030. [Medline].

  244. Wormald R, Evans J, Smeeth L. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2000. CD002030. [Medline].

  245. Wenkstern A, Stokes J. Photodynamic therapy in age-related macular degeneration: missing information. Age Ageing. 2003 May. 32(3):357-9. [Medline].

  246. Verteporfin Roundtable 2000 and 2001 Participants. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002 Feb. 22(1):6-18. [Medline].

  247. Torron Fernandez-Blanco C, Perez Olivan S, et al. [Photodynamic therapy for choroidal neovascularization not caused by age related macular degeneration or pathologic myopia]. Arch Soc Esp Oftalmol. 2003 Sep. 78(9):471-6. [Medline].

  248. Tholen AM, Bernasconi PP, Fierz AB, Messmer EP. [Reading ability after photodynamic therapy (PDT) for age-related macular degeneration (AMD) and for high myopia]. Ophthalmologe. 2003 Jan. 100(1):28-32. [Medline].

  249. Sternberg P Jr, Lewis H. Photodynamic therapy for age-related macular degeneration: a candid appraisal. Am J Ophthalmol. 2004 Mar. 137(3):483-5. [Medline].

  250. Soubrane G, Kuhn D, Coscas G. [Indications for photodynamic therapy in age-related macular degeneration]. J Fr Ophtalmol. 2004 Jan. 27(1):79-80. [Medline].

  251. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol. 2001 Apr. 85(4):483-95. [Medline].

  252. Samkoe KS, Cramb DT. Application of an ex ovo chicken chorioallantoic membrane model for two-photon excitation photodynamic therapy of age-related macular degeneration. J Biomed Opt. 2003 Jul. 8(3):410-7. [Medline].

  253. Ruiz-Moreno JM, Montero JA. Sequential combined therapy for treatment of choroidal neovascularization in age-related macular degeneration: photodynamic therapy and thermal laser photocoagulation. Eur J Ophthalmol. 2003 Oct. 13(8):681-6. [Medline].

  254. Theodossiadis GP, Panagiotidis D, Georgalas IG, Moschos M, Theodossiadis PG. Retinal hemorrhage after photodynamic therapy in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2003 Jan. 241(1):13-8. [Medline].

  255. Porter T, Nesbitt P. Psychosocial implications of clinical trials on patients with age-related macular degeneration and pathologic myopia as seen in the photodynamic therapy trials. Insight. 2001 Apr. 26(2):40-3. [Medline].

  256. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2003. 7(9):v-vi, 1-98. [Medline].

  257. Mandal N, Chisholm IH. Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne). Br J Ophthalmol. 2002 Jan. 86(1):118-9. [Medline].

  258. Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003 Dec. 136(6):1049-61. [Medline].

  259. Isola V, Pece A, Brancato R. Circulatory changes in the choroidal vasculature after verteporfin-based photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina. 2004 Aug. 24(4):618-20. [Medline].

  260. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol. 2004 Aug. 88(8):982-7. [Medline].

  261. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol. 2001 Dec. 16(4):218-22. [Medline].

  262. Gierek-Lapinska A, Wykrota H, Trzciakowski K. [New methods of treatment of age-related macular degeneration. Photodynamic therapy. Part I]. Klin Oczna. 2002. 104(3-4):276-82. [Medline].

  263. Ghazi NG, Jabbour NM, De La Cruz ZC, Green WR. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina. 2001. 21(5):478-86. [Medline].

  264. Cohen SY, Bulik A, Tadayoni R, Quentel G. Visual hallucinations and Charles Bonnet syndrome after photodynamic therapy for age related macular degeneration. Br J Ophthalmol. 2003 Aug. 87(8):977-9. [Medline].

  265. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2002 Jan. 133(1):168-9. [Medline].

  266. Bressler SB, Pieramici DJ, Koester JM, Bressler NM. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No. 6. Arch Ophthalmol. 2004 Mar. 122(3):325-9. [Medline].

  267. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999 Oct. 117(10):1329-45. [Medline].

  268. Ruiz-Oliva F, Cortés J. Verteporfin in Photodynamic Therapy (VIP) Study group. Ophthalmology. 2002 Jun. 109(6):1043; author reply 1043-4. [Medline].

  269. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001 May. 108(5):841-52. [Medline].

  270. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001 May. 131(5):541-60. [Medline].

  271. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol. 2004 Mar. 88(3):344-7. [Medline].

  272. Ahuja RM, Benner JD, Schwartz JC, Butler JW, Steidl SM. Efficacy of transpupillary thermotherapy (TTT) in the treatment of occult subfoveal choroidal neovascularization in age-related macular degeneration. Semin Ophthalmol. 2001 Jun. 16(2):81-5. [Medline].

  273. Auer C, Tao Tran V, Herbort CP. Transpupillary thermotherapy for occult subfoveal neovessels in age-related macular degeneration: importance of patient pigmentation for the determination of laser settings. Klin Monbl Augenheilkd. 2002 Apr. 219(4):250-3. [Medline].

  274. Desmettre T, Maurage CA, Mordon S. Transpupillary thermotherapy (TTT) with short duration laser exposures induce heat shock protein (HSP) hyperexpression on choroidoretinal layers. Lasers Surg Med. 2003. 33(2):102-7. [Medline].

  275. Friberg TR, Pandya A, Nazari K. Transpupillary thermotherapy (TTT) for age-related macular degeneration. Semin Ophthalmol. 2001 Jun. 16(2):70-80. [Medline].

  276. Mueller AJ, Ulbig M, Kampik A. TTT for occult CNV: check the power!. Br J Ophthalmol. 2002 Oct. 86(10):1194. [Medline].

  277. Newsom R. TTT and CNV. Br J Ophthalmol. 2001 Oct. 85(10):1268-9. [Medline].

  278. Newsom RS, McAlister JC, Saeed M, McHugh JD. Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation. Br J Ophthalmol. 2001 Feb. 85(2):173-8. [Medline].

  279. Park CH, Duker JS, Mainster MA, Puliafito CA, Reichel E. Transpupillary thermotherapy (TTT) of occult choroidal neovascularization: a retrospective, noncomparative case series of fifty-seven eyes. Semin Ophthalmol. 2001 Jun. 16(2):66-9. [Medline].

  280. Verma L, Sinha A, Nainiwal S, Tewari HK. Transpupillary thermo therapy for the treatment of choroidal neovascularisation secondary to age related macular degeneration in Indian eyes. Indian J Ophthalmol. 2004 Mar. 52(1):86-7; author reply 87. [Medline].

  281. Verma L, Tewari HK, Nainiwal S, Ravindranathan J. Transpupillary thermotherapy in subfoveal choroidal neovascular membrane secondary to age-related macular degeneration. Indian J Ophthalmol. 2004 Mar. 52(1):35-40. [Medline].

  282. Ciulla TA, Danis RP, Criswell M, Pratt LM. Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. Expert Opin Investig Drugs. 1999 Dec. 8(12):2173-2182. [Medline].

  283. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 2003 May. 110(5):979-86. [Medline].

  284. Ciulla TA, Danis RP, Klein SB, et al. Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. Am J Ophthalmol. 2002 Dec. 134(6):905-6. [Medline].

  285. Sivagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2004 Oct 18. CD004004. [Medline].

  286. Ergun E, Stur M. TTT and CNV. Br J Ophthalmol. 2001 Aug. 85(8):1013. [Medline].

  287. Hammerstein W, Gebauer HJ. [Familial nystagmus and hypoplasia of the macular in reciprocal, balanced translocation 5/16]. Fortschr Ophthalmol. 1989. 86(6):718-21. [Medline].

  288. Takeuchi M, Itagaki T, Takahashi K, Ohkuma H, Uyama M. [Changes in the intermediate stage of retinal degeneration after intravitreal injection of ornithine]. Nippon Ganka Gakkai Zasshi. 1993 Jan. 97(1):17-28. [Medline].

  289. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003 Oct 15. 290 (15):2057-60. [Medline].

  290. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep. 109 (9):1220-31. [Medline].

  291. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999 Oct. 117 (10):1329-45. [Medline].

  292. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001 May. 131 (5):541-60. [Medline].

  293. Yancopoulos GD. Clinical application of therapies targeting VEGF. Cell. 2010 Oct 1. 143 (1):13-6. [Medline].

  294. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009 Dec. 20 (4):158-63. [Medline].

  295. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5. 355 (14):1419-31. [Medline].

  296. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5. 355 (14):1432-44. [Medline].

  297. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011 May. 118 (5):831-9. [Medline].

  298. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008 Feb. 145 (2):239-248. [Medline].

  299. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009 Sep. 116 (9):1731-9. [Medline].

  300. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012 Jun. 119 (6):1175-83. [Medline].

  301. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19. 364 (20):1897-908. [Medline].

  302. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul. 119 (7):1388-98. [Medline].

  303. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul. 119 (7):1399-411. [Medline].

  304. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003 Jan. 9 (1):47-52. [Medline].

  305. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug 20. 99 (17):11393-8. [Medline].

  306. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011 Jun. 118 (6):1098-106. [Medline].

  307. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008 May. 92 (5):667-8. [Medline].

  308. Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011 Jun. 118 (6):1089-97. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.